Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enzo Biochem (GB:0IHV)
LSE:0IHV
Enzo Biochem (0IHV) Share Price & Analysis
0 Followers
0IHV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.13 - $2.68
Previous Close$1.13
Volume800.00
Average Volume (3M)795.00
Market Cap
$58.91M
Enterprise Value-$3.34M
Total Cash (Recent Filing)$69.21M
Total Debt (Recent Filing)$6.95M
Price to Earnings (P/E)-1.2
Beta-1.27
Next Earnings
Jun 10, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding51,225,734
10 Day Avg. Volume65
30 Day Avg. Volume795
Standard Deviation0.16
R-Squared0.08
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.83
Price to Sales (P/S)-7.53
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.16
Enterprise Value/Gross Profit-0.25
Enterprise Value/Ebitda0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Enzo Biochem News
PremiumCompany Announcements
Enzo Biochem Executives Receive Raises and Equity Rewards
PremiumCompany Announcements
Enzo Biochem Announces 2023 Annual Meeting Outcomes
PremiumCompany Announcements
Enzo Biochem Shareholders Elect Directors, Reject Exec PayPremiumCompany Announcements
Enzo Biochem Appoints New CEO and CFO
Options Prices
Currently, No data available
---
Ownership Overview
45.59% Insiders
7.37% Mutual Funds
4.24% Other Institutional Investors
42.79% Public Companies and
Individual Investors
0IHV FAQ
What was Enzo Biochem’s price range in the past 12 months?
Enzo Biochem lowest share price was $1.13 and its highest was $2.68 in the past 12 months.
What is Enzo Biochem’s market cap?
Currently, no data Available
When is Enzo Biochem’s upcoming earnings report date?
Enzo Biochem’s upcoming earnings report date is Jun 10, 2024 which is in 52 days.
How were Enzo Biochem’s earnings last quarter?
Enzo Biochem released its earnings results on Mar 13, 2024. The company reported -$0.061 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.061.
Is Enzo Biochem overvalued?
According to Wall Street analysts Enzo Biochem’s price is currently Overvalued.
Does Enzo Biochem pay dividends?
Enzo Biochem does not currently pay dividends.
What is Enzo Biochem’s EPS estimate?
Enzo Biochem’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enzo Biochem have?
Enzo Biochem has 51,225,735 shares outstanding.
What happened to Enzo Biochem’s price movement after its last earnings report?
Enzo Biochem reported an EPS of -$0.061 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Enzo Biochem?
Among the largest hedge funds holding Enzo Biochem’s share is Evermore Global Advisors, Llc. It holds Enzo Biochem’s shares valued at N/A.
---
Enzo Biochem Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
29.59%
Trailing 12-Months
Company Description
Enzo Biochem
Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.
---
0IHV Earnings Call
Q1 2022
0:00 / 0:00
---
Technical Analysis
---